Identificador per citar o enllaçar aquest ítem: http://hdl.handle.net/20.500.13003/13075
Lysine pathway metabolites and the risk of type 2 diabetes and cardiovascular disease in the PREDIMED study: results from two case-cohort studies
Identificadors
eISSN: 1475-2840
WOS ID: 000497753100001
Scopus EID: 2-s2.0-85074961499
PMID: 31722714
Embase PUI: L629863561
Compartir
Estadístiques
Vegeu estadístiques d'ús d'aquest ítemMetadades
Vegeu el registre Dublin Core de l'ítemAutor
Razquin, Cristina; Ruiz-Canela, Miguel; Clish, Clary B.; Li, Jun; Toledo, Estefanía; Dennis, Courtney; Liang, Liming; Salas-Huetos, Albert; Pierce, Kerry A.; Guasch-Ferre, Marta; Corella, Dolores; Ros, Emilio; Estruch, Ramon; Gomez-Gracia, Enrique; Fito, Montserrat; Lapetra, Jose; Romaguera, Dora ; Alonso-Gomez, Angel; Serra-Majem, Lluis; Salas-Salvado, Jordi; Hu, Frank B.; Martinez-Gonzalez, Miguel A.Data de publicació
2019-11-13Tipus de document
research articleCitació
Razquin C, Ruiz-Canela M, Clish CB, Li J, Toledo E, Dennis C, et al. Lysine pathway metabolites and the risk of type 2 diabetes and cardiovascular disease in the PREDIMED study: results from two case-cohort studies. Cardiovasc Diabetol. 2019 Nov 13;18(1):151.Resum
Background The pandemic of cardiovascular disease (CVD) and type 2 diabetes (T2D) requires the identification of new predictor biomarkers. Biomarkers potentially modifiable with lifestyle changes deserve a special interest. Our aims were to analyze: (a) The associations of lysine, 2-aminoadipic acid (2-AAA) or pipecolic acid with the risk of T2D or CVD in the PREDIMED trial; (b) the effect of the dietary intervention on 1-year changes in these metabolites, and (c) whether the Mediterranean diet (MedDiet) interventions can modify the effects of these metabolites on CVD or T2D risk. Methods Two unstratified case-cohort studies nested within the PREDIMED trial were used. For CVD analyses, we selected 696 non-cases and 221 incident CVD cases; for T2D, we included 610 non-cases and 243 type 2 diabetes incident cases. Metabolites were quantified using liquid chromatography-tandem mass spectrometry, at baseline and after 1-year of intervention. Results In weighted Cox regression models, we found that baseline lysine (HR+1 SD increase = 1.26; 95% CI 1.06-1.51) and 2-AAA (HR+1 SD increase = 1.28; 95% CI 1.05-1.55) were both associated with a higher risk of T2D, but not with CVD. A significant interaction (p = 0.032) between baseline lysine and T2D on the risk of CVD was observed: subjects with prevalent T2D and high levels of lysine exhibited the highest risk of CVD. The intervention with MedDiet did not have a significant effect on 1-year changes of the metabolites. Conclusions Our results provide an independent prospective replication of the association of 2-AAA with future risk of T2D. We show an association of lysine with subsequent CVD risk, which is apparently diabetes-dependent. No evidence of effects of MedDiet intervention on lysine, 2-AAA or pipecolic acid changes was found. Trial registration ISRCTN35739639; registration date: 05/10/2005; recruitment start date 01/10/2003
Versió de l'editor
https://dx.doi.org/10.1186/s12933-019-0958-2MeSH
Cardiovascular DiseasesDiabetes Mellitus, Type 2
Aged, 80 and over
Aged
Randomized Controlled Trials as Topic
2-Aminoadipic Acid
Risk Assessment
Humans
Lysine
Risk Reduction Behavior
Middle Aged
Male
Pipecolic Acids
Biomarkers
Prospective Studies
Time Factors
Female
Risk Factors
Treatment Outcome
Diet, Mediterranean
Primary Prevention
Incidence
DeCS
Dieta MediterráneaIncidencia
Resultado del Tratamiento
Biomarcadores
Factores de Tiempo
Femenino
Conducta de Reducción del Riesgo
Masculino
Factores de Riesgo
Humanos
Persona de Mediana Edad
Ácidos Pipecólicos
Estudios Prospectivos
Lisina
Anciano
Medición de Riesgo
Anciano de 80 o más Años
Diabetes Mellitus Tipo 2
Prevención Primaria
Enfermedades Cardiovasculares
Ensayos Clínicos Controlados Aleatorios como Asunto
Ácido 2-Aminoadípico
Col·leccions de Docusalut en les que apareix aquest ítem
Hospital Universitario Son Espases - HUSE > Comunicación científicaInstituto de Investigación Sanitaria Islas Baleares - IDISBA > Comunicación científica